A Phase 1b, Randomized, Single-Center Trial of Topical Cerdulatinib (DMVT-502) in Patients with Mild-to-Moderate Atopic Dermatitis

Cerdulatinib (DMVT-502) is an investigational kinase inhibitor with demonstrated activity against Jak and SYK (Coffey et al., 2014). There are currently no FDA approved topical Jak/SYK inhibitors for the treatment of atopic dermatitis (AD). Preclinically, cerdulatinib gel (0.2% and 0.4%, representing 0.18% and 0.37% of free base, respectively) was shown to improve epidermal hyperplasia, inflammatory cell infiltration, and hyperkeratosis in an AD mouse model (McHale et al., 2018). This study was designed to evaluate the safety, activity, and target engagement of cerdulatinib gel in patients with mild-to-moderate AD.